THE CANCER IMMUNOTHERAPY PROGRAM at Children’s Hospital of Philadelphia has several clinical trials of chimeric antigen receptor (CAR) T-cell therapy available to eligible patients.
Pilot Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRζ and 4-1BB Signaling Domains in Patients With Chemotherapy-Resistant or Refractory CD19-Positive Leukemia and Lymphoma
Principal Investigator: Stephan A. Grupp, MD, PhD
Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 Attached to TCRζ and 4-1BB Signaling Domains in Patients With Relapsed or Refractory CD19-Positive Leukemia and Lymphoma Previously Treated With Cell Therapy
Principal Investigator: Shannon L. Maude, MD, PhD
Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia
Principal Investigator: Stephan A. Grupp, MD, PhD
Long-Term Follow-up of Patients Exposed to Lentiviral-Based CD19-Directed CAR T-Cell Therapy
Principal Investigator: Stephan A. Grupp, MD, PhD
Pilot Study of Autologous Anti-CD22 CAR-Redirected T Cells in Pediatric Patients With Chemotherapy-Resistant or Refractory Acute Lymphoblastic Leukemia
Principal Investigator: Stephan A. Grupp, MD, PhD
Phase II, Two-Cohort Study of Tocilizumab Optimization Timing for CTL019-Associated Cytokine-Release Syndrome Management in Pediatric Patients With CD19-Expressing Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Principal Investigator: Stephan A. Grupp, MD, PhD
For additional information on these and other trials for pediatric patients, visit Childrens Hospital of Philadelphia at www.chop.edu. ■
